MedPath

Cefazolin

Generic Name
Cefazolin
Drug Type
Small Molecule
Chemical Formula
C14H14N8O4S3
CAS Number
25953-19-9
Unique Ingredient Identifier
IHS69L0Y4T
Background

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication

Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions
Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
Associated Therapies
Antibiotic pre-surgical prophylaxis
Clinical Trials
Related News

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Phase 2
Completed
Conditions
Staphylococcal Bacteraemia
Interventions
First Posted Date
2021-03-01
Last Posted Date
2024-12-10
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
200
Registration Number
NCT04775953
Locations
🇺🇸

Corewell Health - Infectious Disease, Royal Oak, Michigan, United States

🇺🇸

University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States

🇺🇸

University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States

and more 21 locations

PROUD Study - Preventing Opioid Use Disorders

Phase 4
Terminated
Conditions
Opioid Use
Anesthesia
Interventions
Behavioral: Guided mindfulness exercises
Other: Self-administered aromatherapy
Drug: Tylenol/Acetaminophen
Drug: Tranexamic Acid (TXA)
First Posted Date
2021-02-23
Last Posted Date
2023-06-22
Lead Sponsor
Emory University
Target Recruit Count
57
Registration Number
NCT04766996
Locations
🇺🇸

Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States

Prophylactic Antibiotic After Perineal Tear

Not Applicable
Conditions
Puerperal Infection
Interventions
First Posted Date
2021-02-21
Last Posted Date
2021-02-23
Lead Sponsor
Meir Medical Center
Target Recruit Count
2500
Registration Number
NCT04763486
Locations
🇮🇱

Meir Medical Center, Kfar Saba,, Israel

Local Antibiotics for Breast Implants

Phase 3
Recruiting
Conditions
Implant Site Infection
Implant Site Pocket Infection
Implant Complication
Implant Infection
Implant Capsular Contracture
Antibiotic Side Effect
Implant Expulsion
Interventions
Other: Placebo
First Posted Date
2021-01-29
Last Posted Date
2024-05-10
Lead Sponsor
Mikkel Herly
Target Recruit Count
1003
Registration Number
NCT04731025
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

🇩🇰

Aalborg University Hospital, Aalborg, Denmark

and more 5 locations

BonE and Joint Infections - Simplifying Treatment in Children Trial

Phase 4
Recruiting
Conditions
Bone Infection
Septic Arthritis
Bone and Joint Infection
Osteomyelitis
Interventions
First Posted Date
2020-09-03
Last Posted Date
2024-11-08
Lead Sponsor
Murdoch Childrens Research Institute
Target Recruit Count
285
Registration Number
NCT04538053
Locations
🇦🇺

Nepean Hospital, Kingswood, New South Wales, Australia

🇦🇺

John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia

🇦🇺

Sydney Children's Hospital Network, Sydney, New South Wales, Australia

and more 7 locations

A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting

Phase 4
Completed
Conditions
Burn
Surgery
Infection Wound
Interventions
First Posted Date
2020-08-18
Last Posted Date
2022-08-26
Lead Sponsor
Medstar Health Research Institute
Target Recruit Count
32
Registration Number
NCT04516148
Locations
🇺🇸

MedStar Washington Hospital Center, Washington, District of Columbia, United States

Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?

Completed
Conditions
End Stage Renal Disease
Hemodialysis Complication
Infectious Disease
Interventions
First Posted Date
2020-03-24
Last Posted Date
2024-05-16
Lead Sponsor
University of Manitoba
Target Recruit Count
40
Registration Number
NCT04319328
Locations
🇨🇦

College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada

🇨🇦

Saint Boniface Hospital, Outpatient Hemodialysis Unit, Winnipeg, Manitoba, Canada

24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis

Phase 4
Completed
Conditions
Surgical Site Infection
Interventions
Other: 48 hours
Other: 24 hours
First Posted Date
2020-03-11
Last Posted Date
2023-04-11
Lead Sponsor
Saud Al Babtain Cardiac Center
Target Recruit Count
568
Registration Number
NCT04303390
Locations
🇸🇦

Saud AlBabtain Cardiac Center, Dammam, Eastern Province, Saudi Arabia

Supracondylar Pinning Antibiotic Stewardship (SPAS) Trial

Not Applicable
Conditions
Infection
Supracondylar Humerus Fracture
Interventions
Drug: normal saline
First Posted Date
2020-02-28
Last Posted Date
2022-04-12
Lead Sponsor
Legacy Health System
Target Recruit Count
1200
Registration Number
NCT04288206
Locations
🇺🇸

Legacy Emanuel Medical Center, Portland, Oregon, United States

Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty

Not Applicable
Completed
Conditions
Plastic Surgery
Mammaplasty
Anti-bacterial Agents
Prophylaxis
Wound Infection
Interventions
Other: Sterile saline
First Posted Date
2019-09-06
Last Posted Date
2025-02-26
Lead Sponsor
Daniela Francescato Veiga
Target Recruit Count
146
Registration Number
NCT04079686
Locations
🇧🇷

Hospital das Clinicas Samuel Libânio, Universidade do Vale do Sapucaí, Pouso Alegre, MG, Brazil

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy